Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

483 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D'Alfonso TM, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R; International Immuno-Oncology Biomarker Working Group on Breast Cancer. Dieci MV, et al. Among authors: badve s. Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25. doi: 10.1016/j.semcancer.2017.10.003. Epub 2017 Oct 9. Semin Cancer Biol. 2018. PMID: 29024776 Free article. Review.
Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases.
Turbin DA, Leung S, Cheang MC, Kennecke HA, Montgomery KD, McKinney S, Treaba DO, Boyd N, Goldstein LC, Badve S, Gown AM, van de Rijn M, Nielsen TO, Gilks CB, Huntsman DG. Turbin DA, et al. Among authors: badve s. Breast Cancer Res Treat. 2008 Aug;110(3):417-26. doi: 10.1007/s10549-007-9736-z. Epub 2007 Oct 3. Breast Cancer Res Treat. 2008. PMID: 17912629
Re: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system.
Hanna WM, Hammond E, Taylor CR, Dabbs DJ, Penault-Llorca F, Bloom KJ, Bilous M, Badve S. Hanna WM, et al. Among authors: badve s. Mod Pathol. 2008 Oct;21(10):1278-80; author reply 1280-1. doi: 10.1038/modpathol.2008.131. Mod Pathol. 2008. PMID: 18813329 Free article. No abstract available.
Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry.
Yaziji H, Taylor CR, Goldstein NS, Dabbs DJ, Hammond EH, Hewlett B, Floyd AD, Barry TS, Martin AW, Badve S, Baehner F, Cartun RW, Eisen RN, Swanson PE, Hewitt SM, Vyberg M, Hicks DG; Members of the Standardization Ad-Hoc Consensus Committee. Yaziji H, et al. Among authors: badve s. Appl Immunohistochem Mol Morphol. 2008 Dec;16(6):513-20. doi: 10.1097/PAI.0b013e31818a9d3a. Appl Immunohistochem Mol Morphol. 2008. PMID: 18931614
Tumor marker assessment: points to ponder.
Gökmen-Polar Y, Badve S. Gökmen-Polar Y, et al. Among authors: badve s. Cancer Biol Ther. 2011 Jan 15;11(2):284-6. doi: 10.4161/cbt.11.2.14370. Epub 2011 Jan 15. Cancer Biol Ther. 2011. PMID: 21178400 No abstract available.
FOXA1 is an independent prognostic marker for ER-positive breast cancer.
Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S. Mehta RJ, et al. Among authors: badve s. Breast Cancer Res Treat. 2012 Feb;131(3):881-90. doi: 10.1007/s10549-011-1482-6. Epub 2011 Apr 19. Breast Cancer Res Treat. 2012. PMID: 21503684
Breast cancer prognostic markers: where are we now?
Gökmen-Polar Y, Badve S. Gökmen-Polar Y, et al. Among authors: badve s. MLO Med Lab Obs. 2012 Sep;44(9):22, 24-5. MLO Med Lab Obs. 2012. PMID: 23002506 No abstract available.
483 results